Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis

Hitoshi Niikura; Toshimitsu Koizumi; Kiyoshi Ito; Kunihiro Okamura; Nobuo Yaegashi

doi:10.1097/00001813-200310000-00008

Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis

Hitoshi Niikura, Toshimitsu Koizumi, Kiyoshi Ito, Kunihiro Okamura, Nobuo Yaegashi

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m²). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m²) and paclitaxel (135 mg/m ²). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

Original language	English
Pages (from-to)	735-738
Number of pages	4
Journal	Anti-cancer drugs
Volume	14
Issue number	9
DOIs	https://doi.org/10.1097/00001813-200310000-00008
Publication status	Published - 2003 Oct

Keywords

Carboplatin
Endometrial carcinoma
Hemodialysis
Ovarian carcinoma
Paclitaxel

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Access to Document

10.1097/00001813-200310000-00008

Fingerprint Dive into the research topics of 'Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis'. Together they form a unique fingerprint.

Cite this

@article{9d9b8a0217114dcb985f43665a9e983b,

title = "Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis",

abstract = "We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m 2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.",

keywords = "Carboplatin, Endometrial carcinoma, Hemodialysis, Ovarian carcinoma, Paclitaxel",

author = "Hitoshi Niikura and Toshimitsu Koizumi and Kiyoshi Ito and Kunihiro Okamura and Nobuo Yaegashi",

year = "2003",

month = oct,

doi = "10.1097/00001813-200310000-00008",

language = "English",

volume = "14",

pages = "735--738",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis

AU - Niikura, Hitoshi

AU - Koizumi, Toshimitsu

AU - Ito, Kiyoshi

AU - Okamura, Kunihiro

AU - Yaegashi, Nobuo

PY - 2003/10

Y1 - 2003/10

N2 - We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m 2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

AB - We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m 2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

KW - Carboplatin

KW - Endometrial carcinoma

KW - Hemodialysis

KW - Ovarian carcinoma

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0242288101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242288101&partnerID=8YFLogxK

U2 - 10.1097/00001813-200310000-00008

DO - 10.1097/00001813-200310000-00008

M3 - Article

C2 - 14551507

AN - SCOPUS:0242288101

VL - 14

SP - 735

EP - 738

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -